TRC-150094

Summary

Trc-150094 (CHEMBL4297445) is a phase-3 clinical-stage small molecule; indicated across 1 condition including metabolic syndrome x.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 2
• Chemistry: 328.4 Da · C19H24N2O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297445
Name	TRC-150094
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	25125529
Molecular formula	C19H24N2O3
Molecular weight	328.4
InChIKey	OFUOCIUIWKDKPA-UHFFFAOYSA-N

SMILES: CC1=CC(=C2CCCC2=C1O)CC3=C(N(N=C3C)CCC(=O)O)C

IUPAC name: 3-[4-[(7-hydroxy-6-methyl-2,3-dihydro-1H-inden-4-yl)methyl]-3,5-dimethylpyrazol-1-yl]propanoic acid

Also known as: Omzotirome, Trc-150094, TRC-150094, Trc150094, TRC150094

Patent coverage: 8 distinct patent families (27 SureChEMBL compound mentions), from 2 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
metabolic syndrome X	1	MONDO:0011565	EFO:0000195

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03254446	PHASE3	UNKNOWN	Safety and Efficacy Study of TRC150094 to Improve the CV Risk in Subjects With Diabetes, Dyslipidemia and Hypertension
NCT01408667	PHASE1/PHASE2	COMPLETED	Hyperinsulinemic Euglycemic Clamp Protocol

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).